Investment Overview
Blood Cell Technologies is a preclinical biopharma company advancing a first-in-class small-molecule program in hematology. Our platform is built on deep biological validation and is designed for capital-efficient advancement toward value-creating milestones.
Capital Position
The company has secured approximately $5M in non-dilutive funding, including NIH Fast Track support. Funding extends through 2028, supporting lead optimization and IND-enabling activities. This non-dilutive backing reflects external scientific and technical vetting.
Current Opportunity
We are pursuing a bridge round to co-invest alongside existing non-dilutive funding. This capital will accelerate near-term program milestones and position the company for downstream strategic partnerships or institutional financing.
Why Blood Cell Technologies
The company is advancing first-in-class biology addressing a major unmet need in hematology. The program is supported by a strong translational rationale and a clear preclinical execution path. A capital-efficient model leverages non-dilutive funding to reduce investor risk. The leadership team brings deep scientific and operational expertise.
Investor Contact
Lisa Pennacchia, MS
Chief Operating Officer
Lisa@bloodcelltechnologies.com
​
General Inquires: